Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251759 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL3671770 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL29607628 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL2070340 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL15251760 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL6055974 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL13084081 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL3803961 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL5620402 | 1.00 | DRD2 (0.48) | DRD2DRD1CYP19A1KDM1AMAOA | |
| SCHEMBL8885782 | 0.95 | DRD2 (0.46) | DRD2DRD1CYP19A1KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | disclosed |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2024-10-15 | — | — | US | disclosed |
| EP-4215512-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215512-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| EP-3508468-B1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| EP-3508468-B1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11059798-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-11059798-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20080153848-A1 | Crystalline Base of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20080153848-A1 | Crystalline Base of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | H. LUNDBECK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| US-20060281758-A1 | used for the treatment of psychological disorders such as schizophrenia, anxiety, depression and bipolar disorder | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| CN-1839124-A | Succinate and malonate salts of trans-4- ((1R,3S) -6-chloro-3-phenylindan-1-yl) -1, 2, 2-trimethylpiperazine and their use as medicaments | LUNDBECK & CO AS H (DK) | 2006-09-27 | — | — | CN | disclosed |
| EP-1658276-A1 | TRANS-1(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. Lundbeck A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005016901-A1 | TRANS-1(6-CHLORO-3-PHENYLINDAN-1-YL)-3,3-DIMETHYLPIPERAZINE | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016900-A1 | SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND THE USE AS A MEDICAMENT | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059798-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | DRD2 2/4885DRD1 8/4885CYP19A1 2725/4885 |
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | DRD2 2/4885DRD1 8/4885CYP19A1 2725/4885 |
| US-20220119362-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | DRD2 2/4885DRD1 8/4885CYP19A1 2725/4885 |
| US-20080153848-A1 | Crystalline Base of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine | GRIN3A, GRIN2C, SLC6A3 | DRD2 33/4885DRD1 41/4885CYP19A1 3862/4885 |
| US-20080153847-A1 | 2,2-Dimethylpiperazine derivative is reacted with 6-chloro-3-phenyl-indan-1-ol or 6-chloro-3-phenylindan-1-one; salt formation, precipitation, resolution, crystallization, amination, immobilization, catalysis; schizophrenia, psychoses, drug abuse, alcoholism; anxiolytic and antidepressants | ADH1A, ADH1C, ADH5 | DRD2 10/4885DRD1 14/4885CYP19A1 660/4885 |
| US-20060281759-A1 | selective serotonin receptor antagonists used for the treatment of psychological disorders such as schizophrenia and bipolar disorders, as anxiolytic agents and antidepressants; improved water solubility; side effect reduction; | HTR6, HTR1A, HTR2A | DRD2 70/4885DRD1 151/4885CYP19A1 3241/4885 |
| US-20060281758-A1 | used for the treatment of psychological disorders such as schizophrenia, anxiety, depression and bipolar disorder | DRD2, HTR2C, GABBR1 | DRD2 1/4885DRD1 36/4885CYP19A1 3863/4885 |
| US-12116355-B2 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | DRD2 2/4885DRD1 8/4885CYP19A1 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.